GO:0090238 positive regulation of arachidonate secretion: Lipid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090238 describes any process that increases the rate, frequency, or extent of arachidonic acid secretion, the controlled release of arachidonic acid from a cell or tissue.
• Arachidonic acid release is typically initiated by phospholipase A2 (PLA2) enzymes, which hydrolyze membrane phospholipids to liberate free arachidonate.
• Once secreted, arachidonic acid serves as a substrate for cyclooxygenases, lipoxygenases, and cytochrome P450 enzymes to generate eicosanoids that drive inflammation, angiogenesis, and ferroptosis.
• Dysregulated arachidonate secretion is implicated in hepatocellular carcinoma, diabetic kidney disease, sepsis-induced myocardial dysfunction, and non-alcoholic fatty liver disease.
• Key regulators include ACSL4, ENO1, PLA2G7, ALOX15, and the androgen receptor, which modulate arachidonic acid metabolism and downstream signaling.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal interrogation of genes controlling arachidonate secretion in disease contexts.
Description
Arachidonic acid is a polyunsaturated fatty acid that serves as a precursor for a wide array of bioactive lipid mediators. The controlled release of arachidonic acid from cells, termed arachidonate secretion, is a critical step in lipid signaling and is subject to positive regulation by multiple enzymes and signaling pathways. GO:0090238, positive regulation of arachidonate secretion, captures the biological processes that increase the rate, frequency, or extent of this secretion. Understanding this term is essential because arachidonate and its metabolites influence inflammation, cell proliferation, angiogenesis, and ferroptosis, and their dysregulation contributes to cancer, metabolic disorders, and cardiovascular disease. Research into positive regulation of arachidonate secretion has revealed that phospholipase A2 enzymes, particularly the calcium-independent PLA2G7, play a central role in liberating arachidonic acid from membrane phospholipids. Additionally, acyl-CoA synthetase ACSL4 channels arachidonic acid into esterification and ferroptosis pathways, while ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism. The androgen receptor has been shown to promote arachidonic acid metabolism and an angiogenic microenvironment in AFP-negative hepatocellular carcinoma. These findings underscore the importance of precise regulation of arachidonate secretion in health and disease. For researchers, GO:0090238 provides a framework to study how specific genes and signaling cascades modulate arachidonic acid release. Experimental models such as CRISPR knockouts and overexpression systems allow functional validation of candidate regulators. This article synthesizes current knowledge on the mechanisms, key genes, disease associations, and research methodologies relevant to positive regulation of arachidonate secretion, based on authoritative QuickGO data and verified PubMed literature.
positive regulation of arachidonate secretion At A Glance
| GO ID | GO:0090238 |
|---|---|
| GO term | positive regulation of arachidonate secretion |
| Ontology | biological_process |
| Synonym | positive regulation of arachidonic acid secretion |
| Major function | Increases the rate, frequency, or extent of arachidonic acid release from cells or tissues |
| Related processes | Arachidonic acid metabolism, eicosanoid biosynthesis, ferroptosis, inflammatory signaling |
| Key enzymes | Phospholipase A2 (PLA2G7), ACSL4, ALOX15, ENO1 |
| Disease relevance | Hepatocellular carcinoma, diabetic kidney disease, sepsis-induced myocardial dysfunction, NAFLD |
What Is GO:0090238?
GO:0090238, positive regulation of arachidonate secretion, is defined as any process that increases the rate, frequency, or extent of arachidonic acid secretion, which is the controlled release of arachidonic acid from a cell or a tissue. This biological process encompasses molecular events that enhance the secretion of free arachidonic acid, often through the action of phospholipases and downstream signaling pathways.
Why Is positive regulation of arachidonate secretion Important in Cell Biology?
Positive regulation of arachidonate secretion is critically important because arachidonic acid and its metabolites are central to numerous physiological and pathological processes. The release of arachidonic acid from membrane phospholipids is the rate-limiting step in the production of eicosanoids, which modulate inflammation, vascular tone, and cell growth. Dysregulated secretion contributes to cancer progression, metabolic disorders, and cardiovascular diseases, making this process a potential therapeutic target.
• Arachidonic acid is the precursor to prostaglandins, leukotrienes, and thromboxanes, which regulate inflammation and immunity.
• Positive regulation of arachidonate secretion is essential for ferroptosis, a form of regulated cell death implicated in cancer and neurodegeneration.
• ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, linking this process to hepatocellular carcinoma.
• PLA2G7 regulates bone homeostasis via the Alox12/12-HETE/Gpr31 signaling axis, highlighting its role beyond inflammation.
• Androgen receptor promotes arachidonic acid metabolism and angiogenic microenvironment in AFP-negative hepatocellular carcinoma.
• Neutrophil Irgm1 ameliorates sepsis-induced myocardial dysfunction by promoting Alox15 degradation, connecting arachidonate secretion to cardiac injury.
• Diabetic kidney disease involves immune-related ferroptosis biomarkers linked to arachidonic acid metabolism.
• Tibetan medicine Ba-Wei-Chen-Xiang San modulates arachidonic acid metabolism in spontaneously hypertensive rats.
• Brunodelphinine A alleviates non-alcoholic fatty liver disease by regulating lipid metabolism, including arachidonic acid pathways.
• Targeting positive regulators of arachidonate secretion may offer new therapeutic strategies for inflammatory and metabolic diseases.
What Happens During positive regulation of arachidonate secretion?
Activation of Phospholipase A2 Enzymes
In simple terms: Enzymes called phospholipases are switched on to cut arachidonic acid out of the cell membrane.
The first step in arachidonate secretion is the activation of phospholipase A2 (PLA2) enzymes, which hydrolyze the sn-2 position of membrane phospholipids to release free arachidonic acid. PLA2G7, a calcium-independent PLA2, is a key regulator of this process and has been shown to regulate bone homeostasis via the Alox12/12-HETE/Gpr31 signaling axis. Other PLA2 isoforms, such as cytosolic PLA2 (cPLA2) and secretory PLA2 (sPLA2), are also involved in arachidonic acid liberation in response to various stimuli.
Arachidonic Acid Mobilization and Transport
In simple terms: Once freed, arachidonic acid is moved within the cell and prepared for release.
After liberation from phospholipids, arachidonic acid can be re-esterified into membranes or transported to the plasma membrane for secretion. ACSL4, an acyl-CoA synthetase, plays a crucial role in channeling arachidonic acid into esterification and ferroptosis pathways. The balance between re-esterification and secretion is tightly regulated, and positive regulators of secretion enhance the mobilization of arachidonic acid towards the extracellular space.
Signaling Pathways That Enhance Secretion
In simple terms: Specific signaling cascades amplify the release of arachidonic acid.
Multiple signaling pathways positively regulate arachidonate secretion. ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, indicating that YAP1 signaling enhances arachidonic acid release. The androgen receptor promotes arachidonic acid metabolism and an angiogenic microenvironment in AFP-negative hepatocellular carcinoma, suggesting hormonal regulation of this process. Additionally, neutrophil Irgm1 ameliorates sepsis-induced myocardial dysfunction by promoting Alox15 degradation, which indirectly affects arachidonic acid metabolism.
Secretion and Extracellular Release
In simple terms: Arachidonic acid exits the cell to act on neighboring cells or enter the bloodstream.
The final step is the controlled release of arachidonic acid from the cell. Although the exact transporters are not fully characterized, secretion is thought to involve diffusion or specific membrane transporters. Positive regulation of this step increases the extracellular concentration of arachidonic acid, making it available for conversion to eicosanoids by cyclooxygenases, lipoxygenases, and cytochrome P450 enzymes. This release is critical for autocrine and paracrine signaling in inflammation and cancer.
Key Genes Involved in GO:0090238 positive regulation of arachidonate secretion
The following genes and proteins have been experimentally implicated in the positive regulation of arachidonate secretion or its downstream metabolism, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACSL4 | Acyl-CoA synthetase that esterifies arachidonic acid and regulates ferroptosis | Target in ferroptosis and fatty acid metabolism; knockout models show altered arachidonate secretion |
| ENO1 | Enolase 1 promotes YAP1-dependent arachidonic acid metabolism | Oncogenic role in liver cancer; overexpression enhances arachidonate secretion |
| PLA2G7 | Calcium-independent phospholipase A2 that liberates arachidonic acid | Regulates bone homeostasis via Alox12/12-HETE/Gpr31; knockout affects arachidonate release |
| ALOX15 | Lipoxygenase that metabolizes arachidonic acid to 12-HETE | Degraded by Irgm1 in sepsis; modulates myocardial dysfunction |
| AR | Androgen receptor promotes arachidonic acid metabolism | Drives angiogenic microenvironment in AFP-negative HCC; target for therapy |
| ALOX12 | Lipoxygenase that produces 12-HETE from arachidonic acid | Part of PLA2G7 signaling axis in bone homeostasis |
| GPR31 | Receptor for 12-HETE | Mediates effects of arachidonic acid metabolites in bone |
| YAP1 | Transcriptional co-activator downstream of ENO1 | Regulates arachidonic acid metabolism in liver cancer |
| IRGM1 | Immunity-related GTPase that promotes Alox15 degradation | Protects against sepsis-induced myocardial dysfunction |
| NOX4 | NADPH oxidase involved in oxidative stress and lipid metabolism | Modulated by Brunodelphinine A in NAFLD |
| SIRT1 | Deacetylase regulating lipid metabolism | Part of NOX4/SIRT1/PPARs axis in NAFLD |
| PPARs | Nuclear receptors regulating lipid metabolism | Downstream of NOX4/SIRT1 in NAFLD |
| cPLA2 | Cytosolic phospholipase A2 that releases arachidonic acid | General regulator of arachidonate secretion |
| sPLA2 | Secretory phospholipase A2 | Involved in extracellular arachidonic acid release |
| COX-2 | Cyclooxygenase that converts arachidonic acid to prostaglandins | Downstream effector of arachidonate secretion |
| 5-LOX | Lipoxygenase that converts arachidonic acid to leukotrienes | Downstream effector in inflammation |
| CYP450 | Cytochrome P450 epoxygenases | Convert arachidonic acid to epoxyeicosatrienoic acids |
How Is positive regulation of arachidonate secretion Regulated?
Positive regulation of arachidonate secretion is controlled at multiple levels. Transcriptional regulation of PLA2 enzymes, ACSL4, and ENO1 modulates the capacity for arachidonic acid release. Post-translational modifications, such as phosphorylation of cPLA2, enhance its activity. Signaling pathways including YAP1 and androgen receptor signaling increase arachidonic acid metabolism. Additionally, degradation of ALOX15 by Irgm1 affects the balance of arachidonic acid metabolites. The NOX4/SIRT1/PPARs axis regulates lipid metabolism and may influence arachidonate secretion in NAFLD.
positive regulation of arachidonate secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ENO1 | Hepatocellular carcinoma | Knockout and overexpression in liver cancer cell lines |
| AR | AFP-negative hepatocellular carcinoma | Knockdown and overexpression in HCC cells |
| PLA2G7 | Bone homeostasis | Knockout mice and osteoblast cultures |
| IRGM1 | Sepsis-induced myocardial dysfunction | Neutrophil-specific knockout mice |
| ACSL4 | Ferroptosis in diabetic kidney disease | Knockout in kidney cells and ferroptosis assays |
Hepatocellular Carcinoma
ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, and the androgen receptor promotes arachidonic acid metabolism and an angiogenic microenvironment in AFP-negative hepatocellular carcinoma. These findings suggest that positive regulation of arachidonate secretion contributes to tumor progression and angiogenesis in liver cancer.
Diabetic Kidney Disease
Immune-related ferroptosis biomarkers, including those linked to arachidonic acid metabolism, have been identified in diabetic kidney disease, and inhibitors targeting these pathways have been screened. This implicates arachidonate secretion in the pathogenesis of diabetic nephropathy.
Sepsis-Induced Myocardial Dysfunction
Neutrophil Irgm1 ameliorates sepsis-induced myocardial dysfunction by promoting Alox15 degradation, which affects arachidonic acid metabolite levels. This links arachidonate secretion to cardiac injury during sepsis.
Non-Alcoholic Fatty Liver Disease
Brunodelphinine A alleviates non-alcoholic fatty liver disease by inhibiting oxidative stress and regulating lipid metabolism via the NOX4/SIRT1/PPARs axis, which includes arachidonic acid pathways. This suggests that modulating arachidonate secretion may be beneficial in NAFLD.
From positive regulation of arachidonate secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate arachidonate secretion? | CRISPR knockout in cell lines followed by arachidonic acid measurement |
| Does a specific point mutation in PLA2G7 affect its activity? | Point mutation knock-in via CRISPR |
| Does overexpression of ENO1 increase arachidonic acid release? | Overexpression cell models |
| Does tagging ACSL4 with a fluorescent protein affect its localization? | Knock-in of tagged ACSL4 |
| Does androgen receptor signaling enhance arachidonate secretion? | AR overexpression and knockdown in HCC cells |
| Can CRISPR library screening identify novel regulators? | Genome-wide CRISPR knockout library screening |
How to Study the positive regulation of arachidonate secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Arachidonic acid and eicosanoid levels | Quantify secretion in knockout vs wild-type cells |
| CRISPR knockout screening | Genes required for arachidonate secretion | Identify novel regulators |
| RNA-seq | Transcriptional changes in lipid metabolism genes | Assess ENO1 or AR target genes |
| Western blot | Protein expression and degradation | Measure ALOX15 degradation by Irgm1 |
| Immunofluorescence | Subcellular localization of PLA2 enzymes | Visualize arachidonic acid release sites |
| Ferroptosis assays | Lipid peroxidation and cell death | Link ACSL4 to ferroptosis |
| ELISA | Secreted arachidonic acid metabolites | Quantify 12-HETE in bone homeostasis |
| CRISPR knock-in | Tagged protein expression | Track ACSL4 localization |
Lipidomics and Arachidonic Acid Quantification
Mass spectrometry-based lipidomics allows precise quantification of arachidonic acid and its metabolites in cells and tissues. This method is essential for measuring changes in arachidonate secretion upon genetic manipulation.
CRISPR Screening for Regulators
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate arachidonate secretion. Cells are engineered to express a reporter of arachidonic acid release, and sgRNA libraries are used to select for regulators.
RNA Sequencing and Transcriptomics
RNA-seq reveals transcriptional changes in genes involved in arachidonic acid metabolism, such as PLA2G7, ACSL4, and ALOX15, under conditions that modulate secretion.
Proteomics and Phosphoproteomics
Proteomic approaches can identify post-translational modifications and protein interactions that regulate arachidonate secretion, including phosphorylation of cPLA2 and degradation of ALOX15.
How CRISPR Can Be Used to Study GO:0090238 positive regulation of arachidonate secretion
Knockout
CRISPR knockout of genes such as ACSL4, PLA2G7, or ENO1 can abolish their function and reveal their necessity in positive regulation of arachidonate secretion. For example, ACSL4 knockout reduces arachidonic acid esterification and alters ferroptosis sensitivity.
Point Mutation
Introducing point mutations in catalytic residues of PLA2G7 or ACSL4 can dissect their enzymatic activity from scaffolding functions. This approach helps determine whether specific residues are required for arachidonate secretion.
Knock-in
Knock-in of tagged versions of ACSL4 or PLA2G7 allows real-time tracking of protein localization and interaction with membrane phospholipids. This can reveal dynamic regulation of arachidonate secretion.
Overexpression
Overexpression of ENO1 or androgen receptor in cancer cell lines increases arachidonic acid metabolism and secretion, providing gain-of-function evidence for their roles in tumor progression.
How EDITGENE Supports positive regulation of arachidonate secretion Research
Researchers studying positive regulation of arachidonate secretion-related genes often need to determine whether a candidate gene is causally involved in arachidonic acid release or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of arachidonate secretion research.
Frequently Asked Questions About positive regulation of arachidonate secretion
What is GO:0090238?
GO:0090238 is the Gene Ontology term for positive regulation of arachidonate secretion, defined as any process that increases the rate, frequency, or extent of arachidonic acid secretion from a cell or tissue.
What genes are involved in positive regulation of arachidonate secretion?
Key genes include ACSL4, ENO1, PLA2G7, ALOX15, ALOX12, GPR31, AR, IRGM1, and others involved in arachidonic acid metabolism.
How is arachidonic acid secreted?
Arachidonic acid is liberated from membrane phospholipids by phospholipase A2 enzymes and then released from the cell, although the exact secretion mechanism may involve diffusion or transporters.
What diseases are associated with arachidonate secretion?
Dysregulated arachidonate secretion is linked to hepatocellular carcinoma, diabetic kidney disease, sepsis-induced myocardial dysfunction, and non-alcoholic fatty liver disease.
What is the role of ACSL4 in arachidonate secretion?
ACSL4 esterifies arachidonic acid into acyl-CoA, influencing its availability for secretion and ferroptosis.
How does ENO1 regulate arachidonic acid metabolism?
ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, enhancing arachidonate secretion.
What is the function of PLA2G7?
PLA2G7 is a calcium-independent phospholipase A2 that liberates arachidonic acid and regulates bone homeostasis via the Alox12/12-HETE/Gpr31 axis.
Can CRISPR be used to study arachidonate secretion?
Yes, CRISPR knockout, knock-in, and overexpression models allow functional dissection of genes regulating arachidonate secretion.
What methods measure arachidonic acid secretion?
Lipidomics, ELISA, and fluorescent reporters are commonly used to quantify arachidonic acid release.
Why is positive regulation of arachidonate secretion important?
It controls the production of eicosanoids that modulate inflammation, cancer progression, and cardiovascular function.
Conclusion
Positive regulation of arachidonate secretion (GO:0090238) is a critical biological process that governs the release of arachidonic acid, a key precursor to inflammatory and signaling lipids. Research has identified numerous genes, including ACSL4, ENO1, PLA2G7, and ALOX15, that modulate this process in health and disease. Dysregulation of arachidonate secretion contributes to cancer, metabolic disorders, and cardiovascular diseases, making it an attractive therapeutic target. Advances in CRISPR-based gene editing and lipidomics now enable precise interrogation of the regulatory networks controlling arachidonate secretion. EDITGENE offers comprehensive services to support such research, from knockout and knock-in models to library screening and bioinformatics, empowering discoveries that may translate into novel treatments.
References
- 1. Ding K et al.. 2023. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism.. Chin Med J (Engl) 136(21):2521-2537 PMID: 37442770
- 2. Sun L et al.. 2023. ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism.. Nat Chem Biol 19(12):1492-1503 PMID: 37500770
- 3. Jin J et al.. 2025. Pla2g7 regulates bone homeostasis via Alox12/12-HETE/Gpr31 signaling axis.. Nat Commun 16(1):11449 PMID: 41372218
- 4. Zhang NN et al.. 2025. Identification of Immune-Related Ferroptosis Biomarkers in Diabetic Kidney Disease and Screening of Associated Inhibitors.. Curr Med Sci 45(4):799-818 PMID: 40690089
- 5. Wang Z et al.. 2026. Neutrophil Irgm1 ameliorates sepsis-induced myocardial dysfunction by promoting Alox15 degradation.. Redox Biol 92:104104 PMID: 41795420
- 6. Lin Z et al.. 2025. Androgen receptor promotes arachidonic acid metabolism and angiogenic microenvironment in AFP-negative hepatocellular carcinoma.. Nat Commun 16(1):6451 PMID: 40651942
- 7. Wang D et al.. 2026. Pharmacodynamic substance discovery and mechanism of action of Tibetan medicine Ba-Wei-Chen-Xiang San in spontaneously hypertensive rats.. Phytomedicine 155:158156 PMID: 41962268
- 8. Wang M et al.. 2025. Brunodelphinine A alleviates non-alcoholic fatty liver disease by inhibiting oxidative stress and regulating lipid metabolism via NOX4/SIRT1/PPARs axis.. Phytomedicine 147:157202 PMID: 40907406
